-
Mashup Score: 1Current Treatment Options in Third-line MCL - 1 month(s) ago
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Brentuximab Vedotin Plus Lenalidomide and Rituximab Generates OS Benefit in Previously Treated DLBCL - 2 month(s) ago
Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Brentuximab Vedotin Plus Lenalidomide and Rituximab Generates OS Benefit in Previously Treated DLBCL - 2 month(s) ago
Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Brentuximab Vedotin Plus Lenalidomide and Rituximab Generates OS Benefit in Previously Treated DLBCL - 2 month(s) ago
Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Want to learn more from the experts themselves? Listen here as medical oncologists from insitutions across the US gather to discuss third-line treatment options available for patients w/ MCL. @GregNowakowski @JenCrombieMD @lymphomaphilia #oncology #lymsm https://t.co/rgP5XbvPhE